The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study
Abstract
PURPOSE: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). PATIENTS AND METHODS: Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m 2 day (D) 1, methotrexate 3 g/m 2 D1; D15, VP16 100 mg/m 2 D2, BCNU 100 mg/m 2 D3, prednisone 60 mg/m 2/d D1-D5) followed by two cycles of R-AraC (rituximab 375 mg/m 2 D1, cytarabine 3 g/m 2/D, D1, and D2). Intensive chemotherapy consisted of thiotepa (250 mg/m 2/d D9; D8; D7), busulfan (8 mg/kg D6 through D4), and cyclophosphamide (60 mg/kg/d D3; D2). WBRT delivered 40 Gy (2 Gy/fraction). The primary end point was 2-year progression-free survival. Cognitive outcome was the main secondary end point. Analysis was intention to treat in a noncomparative phase II trial. RESULTS: Between October 2008 and February 2014, 140 patients were recruited from 23 French centers. Both WBRT and ASCT met the predetermined threshold (among the first 38 patients in each group, at least 24 patients were alive and disease free at 2 years). The 2-year progression-free survival rates were 63% (95% CI, 49% to 81%) and 87% (95% CI, 77% to 98%) in the WBRT and ASCT arms, respectively. Toxicity deaths were recorded in one and five patients after WBRT and ASCT, respectively. Cognitive impairment was observed after WBRT, whereas cognitive functions were preserved or improved after ASCT. CONCLUSION: WBRT and ASCT are effective consolidation treatments for patients with PCNSL who are 60 years of age and younger. The efficacy end points tended to favor the ASCT arm. The specific risk of each procedure should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Self-citationLong-term survival in primary CNS lymphoma.
Abrey, L. E., DeAngelis, L. M., & Yahalom, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.859 · Cited by 577
Batchelor, T., Carson, K., O’Neill, A., Grossman, S. A., Alavi, J., New, P., Hochberg, F., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 546
Combined modality therapy for primary CNS lymphoma.
DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 544
Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., Grimm, S., Lai, R. K., Reiner, A. S., Panageas, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4910 · Cited by 500
Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F., Casasnovas, O., Dupriez, B., Souleau, B., Taksin, A.-L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5533 · Cited by 324
Self-citationDelayed Neurotoxicity in Primary Central Nervous System Lymphoma
Omuro, A. M. P., Ben-Porat, L. S., Panageas, K. S., Kim, A. K., Correa, D. D., Yahalom, J., DeAngelis, L. M., & Abrey, L. E. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1595 · Cited by 286
Cognitive functions in primary CNS lymphoma after single or combined modality regimens
Correa, D. D., Shi, W., Abrey, L. E., DeAngelis, L. M., Omuro, A. M., Deutsch, M. B., & Thaler, H. T. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor186 · Cited by 189
Illerhaus, G., Kasenda, B., Ihorst, G., Egerer, G., Lamprecht, M., Keller, U., Wolf, H.-H., Hirt, C., Stilgenbauer, S., Binder, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30050-3 · Cited by 174
Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma
Doolittle, N. D., Korfel, A., Lubow, M. A., Schorb, E., Schlegel, U. S., Rogowski, S., Fu, R. F., Dósa, E., Illerhaus, G., Kraemer, D. F., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318297eeba · Cited by 162
Cited by
Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective
Li, X., Zhang, Y., Wang, C., Wang, L., Ye, Y., Xue, R., Shi, Y., Su, Q., Zhu, Y., & Wang, L. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01480 · Cited by 4
Metadata
- Authors
- Houillier, C., Taillandier, L., Dureau, S., Lamy, T., Laadhari, M., Chinot, O., Moluçon-Chabrot, C., Soubeyran, P., Gressin, R., Choquet, S., Damaj, G., Thyss, A., Abraham, J., Delwail, V., Gyan, E., Sanhes, L., Cornillon, J., Garidi, R., Delmer, A., Tanguy, M.-L., Al Jijakli, A., Morel, P., Bourquard, P., Moles, M.-P., Chauchet, A., Gastinne, T., Constans, J.-M., Langer, A., Martin, A., Moisson, P., Lacomblez, L., Martin-Duverneuil, N., Delgadillo, D., Turbiez, I., Feuvret, L., Cassoux, N., Touitou, V., Ricard, D., Hoang-Xuan, K., Soussain, C., & on behalf of the Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma
- Venue
- Journal of Clinical Oncology
- Published
- 2019-04-01
- Volume
- 37
- Issue
- 10
- Pages
- 823-833
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2917478934
- Cited by
- 287
- References
- 15
- FWCI
- 19.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. https://app.cochat.ai/papers/10.1200/jco.18.00306
- The paper
- Houillier, C., Taillandier, L., Dureau, S., Lamy, T., Laadhari, M., Chinot, O., Moluçon-Chabrot, C., Soubeyran, P., Gressin, R., Choquet, S., Damaj, G., Thyss, A., Abraham, J., Delwail, V., Gyan, E., Sanhes, L., Cornillon, J., Garidi, R., Delmer, A., . . . on behalf of the Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma. (2019). Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.00306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
